{
    "nct_id": "NCT04476537",
    "official_title": "A Phase Ib High-throughput Pancreas Precision Oncology Study Investigating the Feasibility, Efficacy, and Pharmacodynamics of Cell Regulatory-network Analysis Based Therapy Selection in Advanced Pancreatic Adenocarcinoma",
    "inclusion_criteria": "* Be willing and able to provide written informed consent for the trial.\n* Age â‰¥18 years of age on day of signing informed consent.\n* Have histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma or be willing to undergo a biopsy with confirmed pathology prior to starting therapy.\n* Have untreated disease that is unresectable due to being metastatic or locally advanced without potential of surgery as assessed by the treating physician.\n* Subjects who have documented disease recurrence greater than 6 months after completing neoadjuvant or adjuvant chemotherapy for limited disease will be eligible for the study.\n* Have a predicted life expectancy of greater than 6 months.\n* Subjects must have a plan to obtain a new core biopsy of a primary and/or metastatic lesion planned as part of routine care for which consent is obtained separately or (b) consent to be biopsied to satisfy the tissue requirements of this protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Has previously received neoadjvuant or adjuvant chemotherapy for pancreatic cancer unless greater than 6 months has passed since completion of adjuvant or neoadjuvant chemotherapy and initiation of therapy for recurrent or metastatic disease.",
    "miscellaneous_criteria": ""
}